DIVERSIFIED BUSINESS MODEL DELIVERS STRONG RESULTS

SALES WORLDWIDE

$8.9B in sales
+10.6% on organic basis

SALES PERFORMANCE ACROSS ABBOTT

$3.2B
MEDICAL DEVICES

$2.6B
DIAGNOSTICS

$1.1B
MICROBIAL REPRODUCTIVE

$1.9B
NUTRITION

RAISED FULL-YEAR 2020 EPS GUIDANCE2

at least $3.55
ADJUSTED DILUTED EARNINGS PER SHARE

TAKING COVID-19 TESTING TO A NEW LEVEL

>100MM
Tests performed in 2020

$881MM
COVID-19 related sales in 2020

LEADERSHIP ACROSS OUR STRONG PRODUCT PORTFOLIO

Diagnostics
SALES UP 39% (ON AN ORGANIC BASIS)

Advances in Heart Devices

FreeStyle Libre
SALES UP 36% (ON AN ORGANIC BASIS)

Abbott is a global healthcare company committed to improving people’s lives through the domestic manufacturing of medical devices and the deployment of healthcare solutions.

Abbott’s diverse product portfolio includes diagnostics, medical devices, nutritionals, and pharmaceuticals that help people manage chronic conditions, support basic healthcare needs, and improve outcomes for surgical procedures. Abbott’s commitment to innovation and quality is exemplified by our longstanding dedication to the Abbott Way and our 100% employee-owned culture. Today, Abbott employs over 100,000 people in more than 160 countries, and we are proud to be a Fortune 100 and Dow component company. Our mission is to help people live longer, healthier lives through the domestic manufacturing of medical devices and the deployment of healthcare solutions.

1. Sales are adjusted to reflect the impact of currency. When compared to the 2020 comparator period, the impact of currency was +1.1%.

2. EPS guidance provided beyond the first quarter reflects Abbott’s expectation for adjusted diluted earnings per share, excluding restructuring charges. This calculation is consistent with the 2020 diluted EPS guidance provided in Q3 2020 earnings release.